Expert Interview
A Second Look: Discussing the recent approval of Zynyz (Retifanlimab) from Incyte in merkel cell carcinoma (MCC).
Ticker(s): INCYInstitution: Moffitt Cancer Center
- Chief Academic Officer and Director of Regional Therapies at Moffitt Cancer Center; Chair on the Department of Oncologic Sciences at University of South Florida Morsani College of Medicine; Professor of Surgery at University of South Florida Morsani College of Medicine
- Manages 20-35 patients with metastatic uveal melanoma
- Research and clinical interests include the regional therapy treatment of cutaneous melanoma, non-melanoma skin cancers and soft tissue sarcomas; Also the director of regional therapies in the cutaneous oncology department
How many MCC patients do you treat annually?
Added By: wilson_adminCan you describe SoC for MCC?
Added By: wilson_adminHow do you think you would use Zynyz in this indication?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
